Soliris 300 mg Injection
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Soliris 300 mg Injection contains eculizumab, a monoclonal antibody that blocks part of the complement system (protein C5). Its labelling describes it as a treatment for several rare, serious conditions: paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uraemic syndrome (aHUS), generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).
Product Information
The following description reflects information associated with eculizumab and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for paroxysmal nocturnal haemoglobinuria (PNH)
- Described for atypical haemolytic uraemic syndrome (aHUS)
- Described for anti-AChR antibody-positive generalised myasthenia gravis (gMG)
- Described for anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD)
Described Dosage & Administration
- Administered only by a healthcare professional as an intravenous infusion — not self-administered
- Its labelling describes weekly induction doses followed by a maintenance dose every two weeks
- The schedule set by the treating specialist should be followed without interruption
Described Side Effects
Commonly described side effects include:
- Headache
- Nausea
- Fatigue
- Infusion-related reactions
- Described as carrying a serious risk of meningococcal and other encapsulated-bacterial infections
- Described as possibly causing breakdown of red blood cells (haemolysis) if treatment is stopped or delayed
Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Meningococcal vaccination is described as required, generally at least two weeks before the first dose, with antibiotic cover if treatment must start sooner
- Fever, headache with a stiff neck, or confusion should be treated as a medical emergency
- Patients are usually given a patient safety card, per the labelling
- Pregnancy or breastfeeding should be discussed with the prescriber
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains eculizumab, a C5 complement inhibitor, and is described for PNH, atypical HUS, generalised myasthenia gravis and NMOSD. SDO Pharma has not independently verified these claims.
Its labelling highlights an increased risk of serious meningococcal infection and describes meningococcal vaccination before treatment; full risk-management guidance is in the manufacturer’s prescribing information.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.